“Bioinspired Engineering: From Human Organs-on-Chips to Dialysis-Like Therapeutic Devices”
Donald E. Ingber, M.D., Ph.D., is the Founding Director of the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Ingber is a pioneer in the field of biologically inspired engineering. At the Wyss Institute, he currently leads a multifaceted effort to develop breakthrough bioinspired technologies to advance healthcare and to improve sustainability. His work has led to major advances in mechanobiology, tumor angiogenesis, tissue engineering, systems biology, nanobiotechnology and translational medicine. Through his work, Ingber also has helped to break down boundaries between science, art and design.
Prof. Oskar C. Aszmann, M.D. is Associate Professor at the Medical University Vienna, Austria and working in a close collaboration with the company Otto Bock to explore the possibilities and limits of bionic reconstruction. This has led to the establishment of a jointly private/government funded Center for Extremity Reconstruction and Rehabilitation in 2012, directed by Prof. Aszmann. For his recent accomplishments in this field and his care for patients with complex extremity injuries he was awarded by the Royal Society of Medicine, London twice and received the Hans Anderl Award, the most prestigious research prize awarded by the European Association for Plastic and Reconstructive Surgery.
Prof. Edward Leonard, Ph.D. is a Professor of Chemical and Biomedical Engineering at the Columbia University in New York. He has focused on biomaterials and on blood purification technologies and is working on miniaturized dialyses and water removal systems for chronic support. Prof. Leonard has been president of ASAIO and in close contact with many European Universities especially the Medical University in Vienna where he holds an adjunct professor.
Prof. James Long, M.D. is the medical director for the Nazih Zuhdi Transplant Institute in the INTEGRIS Baptist Medical Center in Oklahoma City. As a cardiothoracic surgeon his work with advanced heart failure has included high risk heart surgery, advanced Mechanical Circulatory Support and heart transplantation. His clinical experience with blood pumps began as an investigator with the first ever implantable heart pump approved by the FDA. He then led pivotal programs to expand the use of heart pumps for long-term and permanent use. He has been a leader with initiatives to improve outcomes, quality of life and cost effectiveness. Dr. Long has contributed extensively with knowledge and education to advance the field. He served as president of ASAIO and ISRBP.
Prof. Yoshiyuki Taenaka, has leaded pivotal programs on pulsatile cardiac assist systems and rotary blood pumps at the National Cerebral and Cardiovascular Center in Osaka, Japan. He published important papers on chronic effects of cardiac support and its physiological and histological effects. Since a decade he holds important positions in the Japanese health administration. Prof Taenaka has particularly engaged in international societies and has been president of ISRBP, JSAO and APSAO.
Prof. Heike Walles, Ph.D. is heading the Translational Center “Regenerative Therapies” (TLZ) which is the Wuerzburg branch of the Fraunhofer ISC Stuttgart. Her work is focused in the field of Tissue Engineering, particularly on cancer diseases and novel oncologic therapies and diseases of musculoskeletal system as well as infectious diseases. Based on this expertise she is working on special solutions for cell-based tissue models, cell based processes, applications and biologically vascularized implants.
Prof. Jeffrey L. Winters, M.D. is affiliated to the Mayo Clinic in Rochester, Minnesota. The long-term goal of Dr. Winters’ research is to provide evidence to support or refute the use of apheresis as a treatment for human disease. He seeks to make apheresis a rational, evidence-based area in medicine with practical guidelines for the use of photopheresis, plasma exchange and other procedures. In addition to research in apheresis, Dr. Winters also performs research in areas of immunohematology and complications of blood transfusion.
The following main lectures have already been confirmed:
• Enhanced monitoring of patients with cardiac assist devices
• Dialysis for the masses, how an awkward, expensive, complicated therapy acquired a population of more than 2 million patients.
• Immunadsorptions in transplantation
• Myoelectric control of complex arm prostheses
The following symposia will take place:
• Cardiac remodeling and cardiac assist
• Oxygenators and artificial lung
• Patient daily care (ICCAC Symposium)
• Rehabilitation of VAD patients
• VAD treatment strategies in different societies
• Vascular Prostheses
Dialysis and Apheresis
• Citrate anticoagulation
• Emerging applications for extracorporeal technologies
• Pediatric dialysis
• Society Differences in Blood Purification
• Uremic toxins (EUTOX Symposium)
Biomaterials and Regenerative Medicine
• Bioartificial organs
• ThreeD-Printing and Biofabrication
• Tissue Engineering
• Tissue Regeneration
• Tissue Vascularisation
• Albumin-related open questions in medical therapies (ALBUNET Symposium
• Blood Trauma
• Extracellular vesicles (ASEV Symposium)
• Functional electrical stimulation (IFES Workshop)
• Modelling for Artificial Organs
Corporate Members’ Industry Symposium